Erica Lamberg March 09, 2026 Sinus headaches and pressure, nasal irritation and related symptoms, as well as sinusitis are common issues affecting patients in primary-care practices. These symptoms may be attributable to weather changes, the common cold or flu, or — surprisingly — may manifest as potential side effects of GLP-1 medications. Sinusitis is not commonly […]
Exploring Whether GLP-1 Medications May Cause Sinusitis Read More »
It was a busy week for Eli Lilly and Novo Nordisk. Things kicked off with news about CagriSema, Novo’s GLP-1 plus amylin therapy. The Danish pharma company announced that in a head-to-head trial testing CagriSema against Lilly’s Zepbound in obesity, Zepbound came out on top. Patients who were taking CagriSema lost 20.2% of their weight after 84
Nancy Lapid January 22, 2026 Jan 22 (Reuters) – Many patients using highly effective GLP-1 drugs like Wegovy may not regain lost weight quickly when they stop treatment, according to an analysis of real-world data shared with Reuters that sheds light on a chief concern about the therapies. Among thousands of patients treated at a
Many Patients May Keep Off Lost Pounds After Stopping a GLP-1, US Data Suggests Read More »
F. Perry Wilson, MD, MSCE DISCLOSURES November 24, 2025 Welcome to Impact Factor, your weekly dose of commentary on a new medical study. I’m Dr F. Perry Wilson from the Yale School of Medicine. I’ve referred to GLP-1 agents like Ozempic and Mounjaro as “miracle drugs” — a cure not just for the obesity epidemic but for
What Comes Back When Stopping GLP-1s? – Read More »
Miriam E. Tucker November 05, 2025 ATLANTA — De-escalating GLP-1 therapy from weekly to every-other-week dosing following weight normalization may be an effective strategy for maintaining both weight and metabolic improvements, new findings suggested. “In my clinical experience, people who first reach a normal weight and improve their metabolic health following standard weekly dosing of
De-escalating GLP-1s to Every-2-Weeks Maintenance Option Read More »
TOPLINE: The use of GLP-1 receptor agonists was associated with a substantially lower long-term risk for dry age-related macular degeneration (AMD) than the use of other weight-loss medications in adults with overweight or obesity but without diabetes. However, the use of these drugs was not associated with a lower risk for progression to wet AMD in participants
GLP-1s May Protect Against AMD in Those Without Diabetes – Read More »
by Isabella Backman, Yale University edited by Lisa Lock, reviewed by Robert Egan Editors’ notes GLP-1R agonism results in reduced liver levels of Cyp2e1, and higher blood levels of ethanol. Credit: npj Metabolic Health and Disease (2025). DOI: 10.1038/s44324-025-00077-y Anti-obesity drugs such as semaglutide (Ozempic, Wegovy) are also promising for the treatment of alcohol use disorder and alcohol-associated liver disease,
GLP-1 receptor agonists may protect the liver during alcohol consumption Read More »
by British Medical Journal edited by Sadie Harley, reviewed by Robert Egan Credit: Unsplash/CC0 Public Domain SGLT-2 inhibitor and GLP-1 receptor agonist drugs should be used in all or almost all adults with type 2 diabetes at higher risk of cardiovascular and kidney complications, and in the majority of adults at moderate risk of complications, says a
by Justin Jackson, Phys.org edited by Sadie Harley, reviewed by Robert Egan Credit: Pixabay/CC0 Public Domain A cross-sectional analysis from Yale School of Medicine estimates that approximately 5.8 million adolescents and 11.1 million young adults in the United States meet eligibility criteria for glucagon-like peptide-1 receptor agonists (GLP-1RAs), drugs approved to treat obesity and type 2 diabetes
An estimated 17 million US youth meet criteria for GLP-1RA treatment Read More »
Vitae, vulputate lorem id egestas neque egestas habitant sit ante nec.
✆ Phone (appointments): 714-639-4013
Email: care@imedmg.com
Address: 615 E Chapman Ave, Suite #300, Orange, CA 92866